Document Detail


Differential effects of myosin light chain kinase inhibition on contractility, force development and myosin light chain 20 phosphorylation of rat cervical and thoracic duct lymphatics.
MedLine Citation:
PMID:  21930597     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The intrinsic contractile activity of lymphatics varies in different regions of the body. We have previously shown that cervical lymphatics possess an inherently higher frequency but lower tone at a given pressure when compared to thoracic duct lymphatics. However, the molecular mechanisms modulating the contractile characteristics of these lymphatics are not well understood. Since myosin light chain 20 (MLC(20)) phosphorylation appears to underlie the tonic component of lymphatic contraction, we hypothesized that the thoracic duct would be more sensitive to the modulation of MLC(20) phosphorylation when compared to cervical lymphatics. To test our hypothesis, the contractile activities and MLC(20) phosphorylation of thoracic duct and cervical lymphatics were determined in the absence or presence of the specific myosin light chain kinase (MLCK) inhibitor ML-7 under both isobaric and isometric conditions. Addition of ML-7 at each concentration tested led to a decrease in tone in both vessel types. While ML-7 (10(-6) m) significantly reduced the phasic contraction frequency of cervical lymphatics, it completely stopped phasic contractions of thoracic duct at that concentration. Under isometric conditions the active peak and plateau components of tension were both significantly higher in thoracic duct compared to cervical lymphatics. ML-7 (10(-5) m) significantly decreased both the active peak and plateau tensions of thoracic duct, whereas only the active peak tension of cervical lymphatics was decreased. In thoracic duct MLC(20) di-phosphorylation, but not mono-phosphorylation, was significantly decreased with increasing transmural pressure, whereas in cervical vessels only at the higher pressures tested did MLC(20) di-phosphorylation decrease. ML-7 treatment of the thoracic duct caused a significant decrease in both the mono- and di-phosphorylated forms of MLC(20). However, in cervical vessels ML-7 treatment produced an increase in the mono-phosphorylated MLC(20) form while di-phosphorylated MLC(20) was significantly decreased. These data indicate that thoracic duct has an enhanced sensitivity to MLCK inhibition when compared to cervical lymphatics and while the status of the mono- and di-phosphorylation forms of MLC(20) affects both tonic and phasic components of lymphatic contractions, the pressure-dependent changes in tonic contractions are modulated by the status of the di-phosphorylation of MLC(20) in the lymphatics.
Authors:
Zhanna V Nepiyushchikh; Sanjukta Chakraborty; Wei Wang; Michael J Davis; David C Zawieja; Mariappan Muthuchamy
Related Documents :
16038607 - Intracellular signal cascade in cd4+ t-lymphocyte migration stimulated by interferon-ga...
8395837 - Atrial natriuretic peptide inhibits endothelin-1-induced activation of mitogen-activate...
22564307 - Mcm2 phosphorylation and the response to replicative stress.
9196057 - Gastric inhibitory polypeptide activates map kinase through the wortmannin-sensitive an...
16160607 - Involvement of c-jun nh2 terminal kinase and p38mapk in rapamycin-mediated inhibition o...
6210387 - The enhancing effect of gelatin on aprotinin activity.
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2011-09-19
Journal Detail:
Title:  The Journal of physiology     Volume:  589     ISSN:  1469-7793     ISO Abbreviation:  J. Physiol. (Lond.)     Publication Date:  2011 Nov 
Date Detail:
Created Date:  2011-11-17     Completed Date:  2012-05-30     Revised Date:  2014-09-19    
Medline Journal Info:
Nlm Unique ID:  0266262     Medline TA:  J Physiol     Country:  England    
Other Details:
Languages:  eng     Pagination:  5415-29     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Azepines / pharmacology
Enzyme Inhibitors / pharmacology
Lymphatic System / physiology*
Lymphatic Vessels / physiology
Male
Muscle Contraction
Myosin Light Chains / physiology*
Myosin-Light-Chain Kinase / antagonists & inhibitors*,  physiology
Naphthalenes / pharmacology
Neck
Phosphorylation
Rats
Rats, Sprague-Dawley
Thoracic Duct
Grant Support
ID/Acronym/Agency:
HL-089784/HL/NHLBI NIH HHS; K02 HL86650/HL/NHLBI NIH HHS; R01 HL089784/HL/NHLBI NIH HHS; R01 HL75199/HL/NHLBI NIH HHS; R01 HL80526/HL/NHLBI NIH HHS; R01 HL96552/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Azepines; 0/Enzyme Inhibitors; 0/Myosin Light Chains; 0/Naphthalenes; 109376-83-2/ML 7; EC 2.7.11.18/Myosin-Light-Chain Kinase
Comments/Corrections
Comment In:
J Physiol. 2011 Dec 15;589(Pt 24):5905   [PMID:  22174136 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Losartan abolishes oxidative stress induced by intermittent hypoxia in humans.
Next Document:  Prior endurance exercise prevents postprandial lipaemia-induced increases in reactive oxygen species...